Steed D L, Teodori M F, Peitzman A B, McAuley C E, Kapoor W N, Webster M W
J Vasc Surg. 1986 Jul;4(1):28-32.
During the past 2 years, streptokinase has been used to treat subclavian or axillary vein thrombosis in seven patients of whom two were considered "effort" thromboses and five resulted from use of a central venous catheter. All patients had venography performed before treatment to document the thrombosis, and venography was repeated after streptokinase therapy to determine the status of clot dissolution. Streptokinase was given either systemically or in a lowered dose locally, with low-dose therapy chosen whenever a catheter could be threaded up to the clot through an antecubital vein. Although all seven patients had resolution of their clinical symptoms, only one had complete dissolution of the thrombus. The failure of streptokinase to completely dissolve the thrombus suggests that, although apparent clinical improvement can be achieved after streptokinase infusion, treatment of the underlying cause, whenever possible, may be necessary if complete resolution of the thrombus is to occur.
在过去两年中,链激酶被用于治疗7例锁骨下或腋静脉血栓形成患者,其中2例被认为是“用力性”血栓形成,5例是由于使用中心静脉导管所致。所有患者在治疗前均进行了静脉造影以记录血栓形成情况,并在链激酶治疗后重复进行静脉造影以确定血栓溶解状态。链激酶通过全身给药或局部低剂量给药,只要导管能够通过肘前静脉插入血栓部位,就选择低剂量治疗。尽管所有7例患者的临床症状均得到缓解,但只有1例血栓完全溶解。链激酶未能完全溶解血栓表明,尽管输注链激酶后可实现明显的临床改善,但如果要使血栓完全溶解,尽可能治疗潜在病因可能是必要的。